VNRX-5133-101/102: A Randomized, Double Blind, Placebo-Controlled, Sequential Group, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Repeat Doses of VNRX-5133 in Healthy Adult Volunteers

Trial Profile

VNRX-5133-101/102: A Randomized, Double Blind, Placebo-Controlled, Sequential Group, Dose-Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Repeat Doses of VNRX-5133 in Healthy Adult Volunteers

Completed
Phase of Trial: Phase I

Latest Information Update: 26 Jul 2017

At a glance

  • Drugs VNRX 5133 (Primary)
  • Indications Bacterial infections
  • Focus Adverse reactions; First in man
  • Sponsors VenatoRx Pharmaceuticals
  • Most Recent Events

    • 20 Jul 2017 Status changed from active, no longer recruiting to completed.
    • 13 Jun 2017 Status changed from recruiting to active, no longer recruiting.
    • 11 May 2017 Planned End Date changed from 1 Apr 2017 to 1 Jun 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top